Salonen J S, Vuorilehto L, Eloranta M, Karjalainen A
Farmos Group Ltd., Research Center, Turku, Finland.
Eur J Drug Metab Pharmacokinet. 1988 Jan-Mar;13(1):59-65. doi: 10.1007/BF03189930.
In order to investigate the biotransformation of a new alpha 2-adrenoceptor agonist, detomidine, metabolites were isolated from rat urine by solid phase extraction and purified by TLC. The isolated compounds were structurally analysed by 1H-NMR, MS and GC-MS as such or as their methyl and/or silyl derivatives. In addition to detomidine, which was found in trace amounts, four major metabolites were identified: hydroxymethyldetomidine, the corresponding O-glucuronide, detomidine carboxylic acid, and detomidine mercapturate. Together the identified components make up about 80% of urinary detomidine derived compounds. On the basis of these findings a major biotransformation pathway could be suggested. The reaction sequence is initiated by a hydroxylation. Subsequent glucuronidation, glutathione conjugation or secondary oxidation divide the route into three branches each producing one of the other three identified metabolites.
为了研究新型α2 -肾上腺素能受体激动剂地托咪定的生物转化过程,通过固相萃取从大鼠尿液中分离代谢产物,并经薄层层析法进行纯化。对分离得到的化合物以其本身或其甲基和/或硅烷基衍生物的形式,通过1H -核磁共振、质谱和气相色谱 - 质谱联用进行结构分析。除了痕量的地托咪定外,还鉴定出四种主要代谢产物:羟甲基地托咪定、相应的O -葡萄糖醛酸苷、地托咪定羧酸和地托咪定巯基尿酸。所鉴定出的这些成分共同构成了尿中地托咪定衍生化合物的约80%。基于这些发现,可以提出一条主要的生物转化途径。反应序列由羟基化引发。随后的葡萄糖醛酸化、谷胱甘肽结合或二次氧化将该途径分为三个分支,每个分支分别产生另外三种鉴定出的代谢产物之一。